North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe), is estimated to be valued at US$ 1,283.8 million in 2020 and is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has disrupted the global drug supply due to government-mandated or recommended temporary shutdowns, safety initiatives to ensure health and well-being of employees, insufficient labor force, and restrictions on import and export activities, and travel. Antibiotic manufacturing has been particularly affected, and this is not the first time. In the United States alone, there were 148 antibiotic shortages from 2001 to 2013, and a recent penicillin shortage affected at least 39 countries throughout Europe, the Americas and Asia. As of June 29th 2020, 10.5% of all drug shortages listed by the USFDA were antibiotics. In May 2020, Sandoz, the Novartis generics and biosimilars division, announced the expansion of its manufacturing capacity to maintain a stable supply of generic medicines for patients, while also fulfilling on a number of additional commitments to overcoming COVID-19.
The increasing number of product launches, government initiatives, collaborations, and partnerships by key players are major factors which are expected to drive growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market during the forecast period.
Launch of acute bacterial skin and skin structure infections (ABSSSI) drugs is expected to propel the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market growth over the forecast period. For instance, in September 2019, Cipla Limited and its subsidiary Cipla USA, Inc., announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin for Injection in the U.S. CUBICIN is indicated for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis and others.
Increasing government funding for development of ABSSSI antibiotics is expected to accelerate the market growth during the forecast period. For instance, in April 2020, Paratek Pharmaceuticals, Inc. announced that Biomedical Advanced Research and Development Authority (BARDA) initiated funding to support all of the U.S. FDA post-marketing requirements associated with the approval of NUZYRA of pediatric ABSSSI studies as well as the five-year post-marketing bacterial surveillance study. The total reimbursement cost for these post-marketing commitments is projected to be around US$ 77 million.
The key players in the market are focusing on adopting inorganic growth strategies such as mergers, acquisitions and distribution agreements which is expected to drive growth of the market. For instance, in September 2017, Basilea Pharmaceutica Ltd. announced a distribution agreement with Cardiome Pharma Corp. (for Basilea's antibiotic Zevtera/Mabelio (ceftobiprole) for treatment of ABSSSI in Europe (excluding Nordic countries) and Israel. Under the terms of agreement, Cardiome was granted an exclusive license to commercialize ceftobiprole in more than 30 countries in Europe and Israel.
Browse 61 Market Data Tables and 49 Figures spread through 253 Pages and in-depth TOC on North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics (Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others) and Topical Antibiotics (Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine)), by Infection Type (Hospital Acquired ABSSSI, and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, and Europe), - Forecast to 2027"
To know the latest trends and insights related to North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, click the link below:
Strategic collaborations and distribution agreements by companies are expected to drive growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market during the forecast period. For instance, in March 2017, Melinta Therapeutics, a developer of novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, announced the signing of a development and commercialization agreement. As part of this agreement, Melinta Therapeutics granted Menarini Group exclusive rights to commercialize Delafloxacin (known as Baxdela in the U.S.), an investigational anionic fluoroquinolone, under their own brands in 68 countries in Europe, Asia Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia.
Key Takeaways of the North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:
- The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 3.9% during the forecast period (2020-2027), owing to R&D activities and product launches.
- Among drug type, the oral & parenteral antibiotics segment is expected to hold a major revenue share in 2027, owing to the increasing clinical trials for development of new ABSSSI drugs. For instance, in October 2019, GlaxoSmithKline plc announced that patient dosing has begun in a phase III clinical program investigating gepotidacin, the first in a new chemical class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors, in patients with uncomplicated urinary tract infection (uUTI, also known as acute cystitis), urogenital gonorrhoea (GC) and acute bacterial skin and skin structure infections (ABSSSI).
- Major players operating in the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market are Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.
